Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.90 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333275 | 0.94 | GPR119 (1.00) | GPR119NPY2RCHRM2MCHR1 | |
| SCHEMBL2333263 | 0.90 | GPR119 (0.84) | GPR119NPY2RSMN1; SMN2 | |
| SCHEMBL2332803 | 0.90 | GPR119 (0.84) | GPR119NPY2R | |
| SCHEMBL12334972 | 0.90 | GPR119 (0.84) | GPR119NPY2RMCHR1 | |
| SCHEMBL2336035 | 0.89 | GPR119 (0.83) | GPR119NPY2R | |
| SCHEMBL2338806 | 0.89 | GPR119 (0.83) | GPR119NPY2R | |
| SCHEMBL2337457 | 0.89 | GPR119 (0.83) | GPR119NPY2R | |
| SCHEMBL2329990 | 0.88 | GPR119 (0.81) | GPR119NPY2R | |
| SCHEMBL2332919 | 0.88 | GPR119 (0.80) | GPR119NPY2RSMN1; SMN2 | |
| SCHEMBL2335262 | 0.88 | GPR119 (0.80) | GPR119NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170864-B1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | claimed |
| US-8003796-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | claimed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | claimed |
| US-8513424-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513424-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513424-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120258959-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-11 | — | — | US | disclosed |
| US-20120258959-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-11 | — | — | US | disclosed |
| US-20120258959-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-11 | — | — | US | disclosed |
| US-8232404-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232404-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2170864-B1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2170864-B1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | disclosed |
| US-8003796-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003796-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003796-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| WO-2009012275-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258959-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | GPR119 1/4885NPY2R 267/4885CHRM2 207/4885 |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | GPR119 1/4885NPY2R 268/4885CHRM2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.